Announced details
Chronic tinnitus; tinnitus treatment
Evaluate the app’s efficacy and safety when used for 16 weeks.
The companies are jointly developing a treatment app.
Head office: Chuo-ku, Tokyo; President and Representative Director: Ueno Taro (上野太郎). SUSMED,Inc. is a research and development-focused company promoting digital healthcare. It develops treatment apps for conditions including insomnia disorder and provides clinical development support systems using blockchain technology.
The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal.
The company does not address Contract Value / Offering price.
Tinnitus Clinical Practice Guidelines (Japanese Audiological Society)
Web-Based Survey of Tinnitus Care in Japan (Audiology Japan 67:548-557, 2024)
| Item | Details |
|---|---|
| Names of Products / Services Covered | KRP-DT123 |
| Counterparty | SUSMED,Inc. |
| Counterparty overview | Head office: Chuo-ku, Tokyo; President and Representative Director: Ueno Taro (上野太郎). SUSMED,Inc. is a research and development-focused company promoting digital healthcare. It develops treatment apps for conditions including insomnia disorder and provides clinical development support systems using blockchain technology. |
| Relationship with the Company | The companies are jointly developing a treatment app. |
| Launch date | The confirmatory clinical trial is scheduled to commence, but the specific start date is Not disclosed. An application for approval in Japan is planned following completion of the trial. |
| Applicable area | Chronic tinnitus; tinnitus treatment |
| Quantitative Effects | Evaluate the app’s efficacy and safety when used for 16 weeks. |
| Impact on Business Performance | The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal. |
| Source | Tinnitus Clinical Practice Guidelines (Japanese Audiological Society), Web-Based Survey of Tinnitus Care in Japan (Audiology Japan 67:548-557, 2024) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The objective is to evaluate the app’s efficacy and safety and provide a new treatment option for patients suffering from tinnitus. The companies will advance research and development by leveraging their respective expertise in disease areas, clinical development and sales capabilities, treatment app development platform, and clinical trial system.